Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 15, 2017
Pharmacy Choice - News - Generic Drugs - December 15, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 71     Next >>     Go To Page:

12/15/17 - EU and UK Life Sciences Industry Issue Joint Policy Document on Brexit
Today, the Association of the European Self-Medication Industry, the ABPI, the BioIndustry Association, the British Generics Manufacturers Association, European Biopharmaceutical Enterprises, the European Federation of Pharmaceutical Industries and Associations, the European Confederation of Pharmaceutical Entrepreneurs, the European...
12/15/17 - J B Chemicals & Pharmaceuticals receives supplementary ANDA approval for Atenolol Tablets [India Infoline News Service]
J B Chemicals& Pharmaceuticals announced that the USFDA has approved the Companys supplementary Abbreviated New Drug Application for Atenolol Tablets USP 25 mg, 50 mg and 100 mg manufactured using Companys own bulk drug. The Company had initiated this change as a part of its plant to gradually backward integrate US formulations business.
12/15/17 - Nation/world business briefs for Dec. 15
Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, on Thursday said it would lay off 14,000 workers as part of a global restructuring meant to salvage its ailing business. The restructuring is expected to cut costs by $3 billion by the end of 2019. The current limit says one company can't own TV stations that reach more tha
12/15/17 - Report Summarizes Biosimilars Study Findings from Hanyang University Hospital for Rheumatic Diseases (Comparative effectiveness of the biosimilar...
Report Summarizes Biosimilars Study Findings from Hanyang University Hospital for Rheumatic Diseases. According to news originating from Seoul, South Korea, by NewsRx editors, the research stated, "The first biosimilar infliximab, CT-P13 has been used for the treatment of inflammatory diseases for 4? Our news journalists obtained a quote from the r
12/14/17 - Amneal Pharmaceuticals LLC - Only Generic for Kenalog-40 Injection Just Approved Available through Amneal Biosciences
Annual U.S. sales of Kenalog-40 injection were $146 million according to October 2017 IQVIA market data. Amneal Biosciences LLC, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, is dedicated to the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics, anti-infectives and support...
12/14/17 - Biologics and Biosimilars Treatment for Psoriasis in US 2017 Market Outlook, Research, Trends and Forecast to 2022: WiseGuyReports.Com Publish a New Market Research Report On - Biologics and Biosimilars Treatment for Psoriasis In US 2017 Market Ou
New York, NY 12/14/2017 The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6 bn in 2016 is projected to almost double during the forecast period to reach $12.9 bn in 2021 driven by safety and efficacy improvements of the new generation biologics. The psoriasis treatment market is dominated by topical agents
12/14/17 - EMA approves production at Samsung Biologics 152,000L plant [Arab Times (Kuwait)]
Samsung Biologics second facility at its site in Incheon, South Korea was commissioned in 2013 and received GMP accreditation last year. Samsung Biologics has a 91% stake in Samsung Bioepis and Benepali a biosimilar version of Amgens Enbrel owned by Samsung Bioepis was named as the CMOs main product when it launched an IPO in August 2016.
12/14/17 - Federal Register Extracts
Editorial Note: Rule document 2017-23932 was originally published on pages 52356 through 52637 in the issue of Monday, November 13, 2017. Effective date: This final rule with comment period is effective on January 1, 2018, unless otherwise noted. Comment period: To be assured consideration, comments on the payment classifications assigned to HCPCS
12/14/17 - Global Inhalation And Nasal Spray Generic Drugs Market | Analysis and Opportunity Till 2023 Added By DecisionDatabases
DecisionDatabases is involved in providing research report and company profiles in the Global Inhalation And Nasal Spray Generic Drugs Market in terms of revenue and output/volume. Market drivers, opportunities and restraints are thoroughly studied w...
12/14/17 - Histadrut calls strike over Teva cuts [Arutz Sheva (Israel)]
The Histadrut trade union has called a nationwide strike for Sunday following reports that troubled drug giant Teva Pharmaceutical Industries will cut thousands of jobs. The Calcalist business newspaper said Teva intended to "cut over 4,000 jobs, mainly in the U.S. and Israel" as it was saddled with almost $35 billion in debt. Financial daily Globe
12/14/17 - House Energy & Commerce Subcommittee Issues Testimony From America's Health Insurance Plans
The House Energy and Commerce subcommittee on Health issued the following testimony by Matt Eyles, senior executive vice president and chief operating officer of America's Health Insurance Plans, at a hearing entitled "Examining the Drug Supply Chain":. "Chairman Burgess, Ranking Member Green and members of the subcommittee, I am Matt Eyles, Senio
12/14/17 - House Energy & Commerce Subcommittee Issues Testimony From American Hospital Association
The House Energy and Commerce subcommittee on Health issued the following testimony by Thomas Nickels, executive vice president for government relations and public policy for the American Hospital Association, at a hearing entitled "Examining the Drug Supply Chain":. "On behalf of our nearly 5,000 member hospitals, health systems and other health
12/14/17 - Israeli drugmaker Teva to cut quarter of global work force
Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, says it is laying off 14,000 workers as part of a global restructuring. The company said Thursday that the layoffs represent over 25 percent of its global work force. In a letter to employees, Chief Executive Kare Schultz says the restructuring is "crucial to restoring our
12/14/17 - J B Chemicals & Pharmaceuticals receives supplementary ANDA approval for Atenolol Tablets [India Infoline News Service]
J B Chemicals& Pharmaceuticals announced that the USFDA has approved the Companys supplementary Abbreviated New Drug Application for Atenolol Tablets USP 25 mg, 50 mg and 100 mg manufactured using Companys own bulk drug. The Company had initiated this change as a part of its plant to gradually backward integrate US formulations business.
12/14/17 - JB Chemicals & Pharma gets USFDA nod for hypertension tablets [Algeria Press Service]
JB Chemicals& Pharmaceuticals has received US health regulator`s nod for Atenolol tablets, used in treatment of high blood pressure. "The United States Food and Drug Administration has approved the company`s supplementary Abbreviated New Drug Application for Atenolol tablets USP 25 mg, 50 mg and 100 mg," J B Chemicals& Pharmaceuticals said in a BS
12/14/17 - Kalorama Information Report: Biosimilars Will Reduce Prices, But Don't Expect Generic-Like Savings
More than half of all pharmaceuticals prescribed in the United States in 2017 were generic, totaling sales $197 billion. So says Kalorama Information, a New York City- based healthcare market research firm. "Only the first potential for market size and profit margins is met by biosimilars," said Melissa Elder, analyst for Kalorama Information
12/14/17 - Lupin gets USFDA nod for generic of Safyral tablets [India Infoline News Service]
Pharma Major Lupin announced that it has received final approval for its Tydemy from the USFDA to market a generic version of Safyral Tablets of Bayer HealthCare Pharmaceuticals Inc.. Lupin s Tydemy is the AB rated generic equivalent of Safyral Tablets of Bayer HealthCare Pharmaceuticals Inc.. The stock is currently trading at Rs851.2, up by Rs7
12/14/17 - Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs
CFR Part: "42 CFR Parts 414, 416, and 419". Editorial Note: Rule document 2017-23932 was originally published on pages 52356 through 52637 in the issue of Monday, November 13, 2017. Effective date: This final rule with comment period is effective on January 1, 2018, unless otherwise noted.
12/14/17 - Next Decade Generic String of Pearls Market Research Report 2017 Global Analysis and Forecast to 2022: WiseGuyReports.Com Publish a New Market Research Report On - Next Decade Generic String Of Pearls Market Research Report 2017 Global Analysis an
New York, NY 12/14/2017 The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In this era of increased pharmaceutical industry competition, success for gen
12/14/17 - Pfizer Biosimilar Medicine IXIFI Gets FDA Approval For All Eligible Indications
NEW YORK CITY- Pfizer Inc. announced that the United States Food and Drug Administration has approved IXIFI or PF-06438179, infliximab-qbtx, a chimeric human-murine monoclonal antibody or mAb against tumor necrosis factor, as a biosimilar to Remicade or infliximab for all eligible indications of the reference product. Pfizer has a portfolio of thre
12/14/17 - Sanofi wins US approval for follow-on Humalog insulin copy [Algeria Press Service]
The US FDA has approved Admelog as a follow-on drug five months after it received European market authorisation as a biosimilar of Eli Lillys Humalog. This was because Sanofi submitted Admelog to the FDA through the 505 pathway, making it a and a follow-on product, spokesperson Anna Robinson said, and not through the dedicated biosimilar 351 pathwa
12/14/17 - Teva Pharmaceutical to lay off 14,000 globally; effect on Gurnee facility unclear [Chicago Tribune]
Dec. 14 Israel- based Teva Pharmaceutical Industries which has nearly 100 employees in Illinois announced plans Thursday to cut 14,000 jobs globally. It was not immediately clear whether the Illinois employees, who work at a distribution center in Gurnee, will face layoffs. The company plans to consolidate seven U.S. offices not including t
12/13/17 - Alembic Pharma gains on USFDA approval for Darifenacin [All Iraq News Agency (AIN)]
Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application Darifenacin Extended- Release Tablets, 7.5 mg and 15 mg. Alembic Pharmaceuticals, a leading pharmaceutical company, is a market leader in the macrolides segment of anti-infective dr
12/13/17 - Alembic Pharmaceuticals gets USFDA go-ahead for bladder drug [Arab Times (Kuwait)]
Alembic Pharmaceuticals has received US health regulator`s nod for a drug used to treat overactive bladder with symptoms of urinary incontinence, urgency and frequency. "The company has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Darifenacin extended release tablets, 7.5 mg and
12/13/17 - Aurobindo Pharma gets USFDA approval for Reclast generic [India Infoline News Service]
Aurobindo Pharma gets USFDA approval for Reclast generic. The stock to react positively to this news, as it will consolidate the company s position in the US generic market and improve its US Sales. Aurobindo Pharma Ltd is currently trading at Rs 681.2, up by Rs 3.95 or 0.58% from its previous closing of Rs 677.25 on the BSE.
Articles(s): 1 - 25 of 71     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415